Results: Pooled data from IDE clinical trials revealed that EG patients were 3 years older (73 ؎ 8 years) than SC patients (70 ؎ 8 years, P < .01) and had significantly more cardiac comorbidities before treatment. However, there was no difference in 30-day operative mortality between EG (1.7%) and SC (1.4%) (P ‫؍‬ .72). Both EG and SC were successful in preventing rupture, with freedom from aneurysm rupture in 99.8% of EG and 100% of SC patients at 1 year (P ‫؍‬ .51). Freedom from rupture remained at 99% in years 1 to 6 after EG, with no increasing risk of late rupture. There was no significant difference in the AAA-related death rate at 1 year between EG (98.2%) and SC (98.6%) (P ‫؍‬ .64). Freedom from AAA-related death remained at 98% in years 1 to 6 after EG, with no increasing risk of late AAA-related death. Kaplan-Meier analysis at 6 years revealed freedom from aneurysm rupture in 99%, freedom from AAA-related death in 98%, and freedom from surgical conversion in 95% of EG patients. There was no difference in survival at 4 years between EG (74%) and SC (71%) (P ‫؍‬ .49). Overall EG patient survival at 5 years was 66% and at 6 years was 52%. Women had a higher risk of rupture (2.4%) than men (1.2%) (P ‫؍‬ .01) and a higher rate of surgical conversion (8.3%) than men (3.8%) (P < .01) but had the same low AAA-related death rate (3.5%) as men (2.1%) (P ‫؍‬ .16) at 5 years. Most secondary interventional procedures (85%) were performed <30 days after EVAR. Freedom from secondary intervention was 84% at 1 year and 78% at 5 years. 
The Lifeline Registry of Endovascular Aneurysm Repair (EVAR) was established in 1998 to evaluate the longterm outcome of endovascular treatment of patients with infrarenal abdominal aortic aneurysms (AAA). A standardized reporting format was developed to allow pooling of data from patients treated with endovascular grafts from different manufacturers to determine the overall effectiveness of EVAR. 1, 2 Since 1999, the United States Food and Drug Administration (FDA) has approved five endovascular grafts for clinical use in the United States: the Guidant AnCure (Indianapolis, Ind), Medtronic AneuRx (Santa Rosa, Calif), Gore Excluder (Flagstaff, Ariz), Endologix PowerLink (Irvine, Calif) and Cook Zenith (Bloomington, Ind). Each device was approved on the basis of a multicenter, controlled Investigational Device Exemption (IDE) clinical trial comparing the endograft (EG) to open surgical repair (surgical controls, SC). Each IDE clinical trial was sponsored by the manufacturer of the device, and the protocol, inclusion and exclusion criteria, and clinical results have been individually pub lished. [3] [4] [5] [6] [7] A condition of FDA approval for each of these devices was clinical and imaging follow up of all EG patients for a 5-year period after completion of the clinical trial. The manufacturers of four of the FDA-approved devices (AnCure, AneuRx, Excluder, and PowerLink) submitted their IDE clinical trial data on EG and SC patients along with long-term follow up data to the Lifeline Registry. This report is focused on the primary outcome measures of endovascular aortic aneurysm repair, namely operative mortality, aneurysm-related death, all-cause mortality, aneurysm rupture, and surgical conversion.
METHODS
All clinical data from the four IDE clinical trials submitted by the manufacturers are included in the registry. Data was received as Statistical Analysis System (SAS) datasets (SAS Institute Inc, Cary, NC) or Excel (Microsoft, Bellingham, Wash) spreadsheets and converted to the common registry data format by matching variable names from the manufacturer case report forms to the registry case report forms. Discrepancies between definitions of endpoints are footnoted, when appropriate; for example, AAA enlargement is defined as a Ͼ5-mm increase from predischarge, while one manufacturer compares it to 30 days. Pooled data from patients treated with endovascular grafts under controlled IDE clinical trials (EG-IDE) were compared with pooled data from surgical control (SC) patients from these same clinical trials.
Complete 1-year follow-up was required for both EG and SC groups in accord with the IDE protocols. Complete 5-year follow-up of EG-IDE patients, including aneurysm imaging, was required of manufacturers as a condition of FDA approval. Long-term follow up requirements Ͼ1 year for SC patients was limited to survival status.
The primary outcome measures of aneurysm repair were:
(a) operative mortality, defined as death during the initial hospitalization or death from any cause Յ30 days of the primary procedure; (b) aneurysm-related death, defined as death from any cause Յ30 days of the primary procedure, death Յ30 days of a secondary procedure or surgical conversion, or any death due to aneurysm rupture or graft complication; (c) all-cause mortality (survival); (d) aneurysm rupture; and (e) conversion to open surgical aneurysm repair.
Secondary outcome measures for EG such as endoleak, aneurysm sac enlargement, endograft migration, and graft patency are not considered in this analysis; however, the overall secondary interventional procedure rate is reported.
Statistical analysis. Baseline characteristics of the EG and SC groups were compared by using the two-tailed t test for continuous variables and the 2 or Fisher's exact test, as necessary, for discrete/categoric data. Descriptive statistics are listed as mean Ϯ standard deviation for continuous variables and percent (frequency) for categoric variables. Kaplan-Meier estimates, using the log-rank test, were used to compare the primary outcome between groups for freedom from death (ie, survival), aneurysm-related death, rupture, and conversion to open repair. Differences were considered significant if P Ͻ .05. The Cox proportional hazard multivariate logistic regression was performed to assess predicate factors of outcome (ie, potential independent risk factors). All statistical analyses were performed by New England Research Institutes, Inc, (NERI) in Watertown, Mass.
RESULTS
Patient population. The numbers of patients from each of the IDE clinical trial included in the Lifeline Registry are shown in Table I . The registry contains 2,664 Table II . There were statistically significant differences between the EG-IDE group and the SC group before aneurysm treatment. Endovascular patients were an average of 3 years older (73 vs 70 years, P Ͻ .01) and had significantly more coronary artery disease (83% vs 59% in SC, P Ͻ .01) and congestive heart failure (11% vs 6% in SC, P ϭ .01) than surgical controls. Surgical control patients were more likely to be Ͻ65 years old (24% vs 13% in EG, P Ͻ .01) and more likely to be women (21% vs 13% in EG, P Ͻ .01).
There was no difference in preoperative aneurysm size between EG and SC, with mean a aneurysm diameter of 5.6 Ϯ 1.0 cm in EG patients and 5.7 Ϯ 1.2 cm in SC patients. Mean follow-up time was 2.8 Ϯ 1.6 years (maximum, 6.7 years) for the EG-IDE group and 1.9 Ϯ 1.4 years (maximum, 4.3 years) for the SC group.
Primary outcome measures. Kaplan-Meier analyses of the primary endpoints for EG-IDE patients extended to 6 years and are shown on Figs 1 to 4.
Operative mortality. The 30-day operative mortality was 1.7% for the EG-IDE group and 1.4% for the SC group. There was no significant difference in operative mortality rate between EG-IDE and SC patients (P ϭ .72). Operative mortality in the EG-IDE group for men was 1.5% compared with 2.1% for women (P ϭ .42). Operative mortality in the SC group for men was 1.1% compared with 1.5% for women (P ϭ .48).
AAA-related death. Most AAA-related deaths (80%) occurred during the initial 30-day perioperative period (30-day operative mortality noted previously). Three AAA-related deaths occurred in the interval 30 days to 1 year in the EG-IDE group and none in the SC group. There was no significant difference in AAA-related death rate at 1 year between EG-IDE (1.8%) and SC (1.4%) (P ϭ .63, Kaplan-Meier log rank test). Eight AAA-related deaths occurred in the EG patients from years 1 to 6. Freedom from AAA-related death after EG by Kaplan-Meier analysis remained unchanged at 98% from years 1 to 6, with no increasing risk of late AAArelated death (Fig 1) . The only significant predictor of AAA-related mortality was a larger preoperative aneurysm size, as seen in Table III , A .
All-cause mortality (survival). There was no significant difference in survival between EG-IDE and SC patients (Fig 2) . Survival data extended to 6 years in EG-IDE patients but was limited beyond 4 years in the SC group (the longest SC follow-up time was 4.3 years). The KaplanMeier survival comparison between groups was, therefore, performed at 4 years. There was no difference in survival at 4 years between SC (71%) and EG-IDE (74%) (P ϭ .49). Survival for EG-IDE at 5 years and 6 years was 66% and 52%. Significant predictors of all cause-mortality included increased age and the presence of comorbid factors, including coronary artery disease/myocardial infarction, congestive heart failure, chronic obstructive pulmonary disease, and renal failure, as listed in Table III , B. Larger preoperative aneurysm size was also a significant predictor of mortality.
Rupture. No aneurysm ruptures were reported among SC patients, and 18 ruptures occurred among EG patients. These included three early (Ͻ30 days) and 15 late ruptures (Ͼ30 days). Ruptures were reported from three of the four IDE clinical trials in the registry. There was no difference in freedom from aneurysm rupture between EG-IDE patients (99.8%) and SC patients (100%) at 1 year by Kaplan-Meier analysis (log-rank test, P ϭ .51) (Fig 3) . The late aneurysm rupture rate was not available for SC patients.
The freedom-from-rupture rate for EG patients remained at 99% from years 1 to 6, with no suggestion of an increasing late risk of rupture after EG. Significant predictors of increased risk of aneurysm rupture were female gender and preoperative aneurysm size, as listed in Table  III , C. Women had a threefold increase in risk of rupture compared with men (hazard ratio, 3.4; P ϭ .03).
Surgical conversion. Open surgical repair after primary aneurysm treatment was reported from each of the IDE clinical trials in the registry and was confined to the endograft patient group. Among the EG-IDE patients, 96 patients have required conversion to open repair. Of these, 68 (71%) were early (Յ30 days of the primary procedure), and many occurred during the early experience with EVAR. There have been 28 late surgical conversions (30 days to 6 years). The 30-day operative mortality rate for early surgical conversion was 5 (7.4%) of 68 and for late surgical conversion was 0 (0%) of 28. Freedom from surgical conversion was 97% at years 1 through 3, 96% at year 4, and 95% at years 5 and 6 (Fig 4) .
Predictors of the need for surgical conversion were female gender, coronary artery disease/myocardial infarction and larger preoperative aneurysm size, as seen in Table  III , D. Women had a threefold higher likelihood of needing surgical conversion than men (hazard ratio, 3.7; P Ͻ .01).
Secondary interventions. Secondary interventional procedures after the primary index procedure were reported in the endograft patient group. Among the EG-IDE patients, 487 patients have required a secondary intervention. Of these, 415 (85%) were early (Յ30 days of the primary endograft procedure). There have been 76 late surgical conversions (30 days to 6 years). Freedom from secondary intervention was 84% at 1 year, 83% at 2 years, 82% at 3 years, 81% at 4 years, 78% at 5 years, and 73% at 6-years (Fig 5) .
Gender analysis-endovascular group. A primary outcome analysis by gender of the EG-IDE showed a significant difference in age between women and men, with women being 3.6 years older (76.4 Ϯ 7.7 years; range, 28 to 96 years) than men (72.8 Ϯ 7.8 years; range, 45 to 96 years) (P Ͻ .01). However, there was no significant difference in all-cause mortality or AAA-related mortality between women and men by Kaplan-Meier analysis. Operative mortality (30 day) for women (2.2%) compared with men (1.5%) was not significantly different (P ϭ .42). Cumulative AAA-related death at 5 years was not significantly different for women (3.3%) than for men (2.1%) (P ϭ .25, log-rank test). Survival at 5 years was no different in women (60%) than in men (67%) (P ϭ .31). Women had a twofold greater risk of aneurysm rupture (2.5%) than men (1.2%) (P ϭ .01). Women were also more likely to require surgical conversion (8.5%) than men (3.9%) (P Ͻ .01); however, this difference was entirely due to a higher risk of early (Ͻ30 day) conversion among women (17 of 19 conversions occurred during the perioperative period). There was no difference in late surgical conversion rate between women and men.
Aneurysm size analysis. Preoperative aneurysm size was reported in 2,019 EG patients. Of these, 1,040 were small aneurysms (Ͻ5.5 cm) and 979 were large aneurysms (Ն5.5 cm). Preoperative aneurysm size was a significant predictive factor for all primary end points (all-cause mortality, aneurysm-related mortality, rupture, and surgical conversion) as summarized in Table  III , A to D . During the 5-year follow-up period, patients with large aneurysms had a threefold higher risk of rupture (2.4%) than patients with small aneurysms (0.7%) (P ϭ .01). However, there was no difference in the 5-year AAA-related death rate (3.0% in large AAA and 2.0% in small AAA) (P ϭ .21, log-rank test) or the 5-year surgical conversion rate (5.3% in large AAA and 4.2% in small AAA) (P ϭ .20, log-rank test) between patients with large and small aneurysms. Patients with large aneurysms had a reduced survival at 5 years (64%) compared with patients with small aneurysms (69%) (P Ͻ .01).
DISCUSSION
The Society for Vascular Surgery established the Lifeline Registry to monitor the long-term safety and effectiveness of EVAR using FDA-approved devices. To this end, an effort was made to include data from each of the controlled IDE clinical trials, which are the basis for FDA device approval. Since the FDA mandated 5-year monitored, clinical, and imaging follow-up of each IDE patient cohort as a condition of approval, this provided a unique opportunity for the most comprehensive long-term perspective of EVAR.
The registry, working in cooperation with industry and NERI, established a mechanism for data management, uniform reporting, and pooling of long-term outcomes from the various clinical trials. The manufacturers agreed to share their data with the registry, granting oversight of the data to the registry steering committee to release pooled 
data and analyses without identifying individual device(s).
With the assistance of IDE trial data managers, NERI successfully incorporated the IDE datasets of four of the five FDA-approved EGs into a common database.
Because each of the IDE trials was independently designed to compare a single EG with its surgical control group for purposes of FDA market approval, there was no uniformity among the trials with regard to numbers of patients, inclusion and exclusion criteria, or definitions of endpoint variables. Nonetheless, the similar long-term end points and completeness of follow-up far outweighed the differences among the IDE trials. This allowed meaningful data pooling reflecting the overall results of EVAR rather than the outcomes of any specific device. The results of individual EG-IDE trials have been published and are available in the literature [3] [4] [5] [6] [7] [8] [9] along with publications that compare differing devices. [10] [11] [12] The Lifeline Registry data show that EVAR is a safe and effective treatment for selected patients with infrarenal AAA and that EVAR appears to be durable out to 6 years of follow-up. The safety of EVAR was demonstrated by a low operative mortality rate (1.7%), which was no different from surgical controls (1.4%). It should be noted that this low operative mortality rate was achieved even though EG patients were significantly older and sicker than the SC patients and included patients at high risk for open surgery. Current operative mortality rates for men and women undergoing elective open surgical repair are reported to be 5% to 6%. [13] [14] [15] [16] [17] Although some reports suggest a higher operative mortality rate for women undergoing open repair, 18, 19 there was no difference in operative mortality between women and men in the Lifeline Registry.
Effectiveness of EVAR was demonstrated by a low likelihood of aneurysm rupture among patients treated with EG, with only 18 early and late ruptures (0.6%). Kaplan-Meier analysis revealed a 1.3% cumulative risk of rupture at 5 years among 2,664 EG-IDE patients. This is lower than the 1% per year rupture rate of small aneurysms (Ͻ5.5 cm) followed in prospective, randomized clinical trials. 20, 21 The risk of rupture after EVAR was three times higher in women (2.1%) than men (0.7%), which is consistent with other reports of a three-to fourfold increase in rupture risk among women. 20, 22, 23 Although no ruptures were reported among surgical controls in the registry, follow-up of SC patients after 1 year was not as rigorous as EG patients, with a requirement to report only survival status. Prospective clinical trials of open aneurysm repair report that the risk of rupture is not eliminated after open repair. [13] [14] [15] 22 Durability of EVAR was demonstrated by a persisting low risk of aneurysm rupture and AAA-related death. Rupture rate remained stable at 1% by Kaplan-Meier analysis over a 6-year period, with no suggestion of an increasing risk of late rupture. Similarly, AAA-related death rate remained stable at 2% by Kaplan-Meier analysis over a 6-year period with no suggestion of an increasing risk of late AAA-related death. These results are in contrast to EURO-STAR Registry reports showing an increasing risk of late rupture and AAA-related death 3 years after EVAR. 24, 25 These differences may be related to the high proportion of patients in the EUROSTAR Registry treated with early EGs that are no longer in clinical use. 24, 26, 27 Durability was further demonstrated by a low surgical conversion rate of 3% at 1 year and 5% at 6 years by Kaplan-Meier analysis, with no increasing risk of late conversions. Late surgical conversions were well tolerated, with no deaths among the 28 patients requiring conversion Ͼ30 days after the primary procedure. By contrast, the EURO-STAR Registry found an increasing risk of late surgical conversion, with 9% of patients requiring conversion at 4 years. 24, 25 The Lifeline Registry found a higher risk of surgical conversion in women, which was largely related to perioperative issues of small iliac access arteries (19 of 21 conversions in women occurred Յ30 days). There was no increased risk of late conversion (Ͼ30 days) in women (2/225, 0.9%) compared with men (19/1875, 1.0%). Interestingly, although women experienced a higher risk of both surgical conversion and rupture, there was no difference in AAA-related death between women and men in the Lifeline Registry.
Despite the fact that the Lifeline Registry contains significant numbers of SC patients, evaluation of long-term outcomes of EVAR compared with open surgery is compromised by the limited long-term data for SC patients. Although the FDA required 5-year follow-up data on all EG-IDE patients, survival status alone was required on SC-IDE patients after 1 year. No late SC patient deaths in the registry were reported to have been due to an aneurysm-related cause and no late ruptures were recorded among SC patients. However, ruptures have been reported after successful elective open surgical repair in prospective clinical trials. 14, 15, 20 In a study of late outcome after elective open aneurysm repair, Hallett et al 28 found that 2.6% of patients died as a result of some graft-related complication at a mean follow-up time of 5.8 years. Published results on the long-term outcome of open repair suggest that late AAA-death rates range from 0% to 0.63% per year, with a mean annual rate of 0.28%. 18, 21, [28] [29] [30] Five-year survival after EVAR was lower in Lifeline (66%) than in the EUROSTAR Registry (75%). 24 However, it should be noted that EG patients in Lifeline were 2 years older (73 years) than patients in EUROSTAR (71 years). 25 Five-year survival after open repair has been reported to be 64% to 77%. 3, 14, 15, 18, 21 The primary predictors of mortality in Lifeline were similar to other reports, namely age, cardiac comorbidity, and preoperative chronic obstructive pulmonary disease and renal failure. Although women in Lifeline were 3 years older than the men, there was no statistically significant difference in 5-year survival between women and men.
Most patients in the Lifeline Registry are from the Guidant AnCure and Medtronic AneuRx clinical trials, which were the first IDE clinical trials and the first devices to be approved by the FDA. Most of the surgical conversions in the registry are from the early EVT/AnCure IDE experience, which includes the initial EVAR learning phase for most investigators in the trial. The surgical conversion rate decreased significantly in later phases of the Guidant trial.
3 Surgical conversions were not, however, limited to the AnCure device and have occurred with all endovascular devices in the registry. Most ruptures in the registry are from the early AneuRx IDE experience. Published reports from the AneuRx trial indicated that the risk of rupture was higher in patients treated with the early "stiff" device, which was later replaced with a flexible design. 38 Ruptures have been reported with all endovascular devices 5, 8, 9, 33, 38 and occurred in three of the four IDE clinical trials in the registry. The rupture risk with each of the devices in the registry is very low, and the risk does not appear to increase in late follow-up. Nonetheless, the potential for rupture remains with all devices, and patients should continue to be closely followed over time.
Secondary outcome measures after EVAR, such as endoleak, aneurysm enlargement, endograft migration, and secondary interventions were not the subject of this report. These secondary end points have been discussed extensively in the literature. 24, [31] [32] [33] [34] [35] [36] [37] Most of the secondary interventional procedures (85%) in the Lifeline Registry were performed Յ30 days after the endograft procedure. Although secondary interventional procedures were required in 16% of EG patients after 1 year and 22% of EG patients after 5 years, the long-term primary outcome measures of EVAR remained stable, with no suggestion of diminishing favorable long-term results. It should be recognized, however, that Lifeline data extends only through 6 years, and that continuing and ongoing long term follow up will be required of EG patients to determine the ultimate long-term outcome.
CONCLUSIONS
Endovascular aneurysm repair using FDA-approved endografts is safe and effective in preventing aneurysm rupture and avoiding AAA-related death in the great majority of patients undergoing treatment. EVAR is durable, with a low long-term risk of rupture and AAA-death and a low likelihood that surgical conversion will be needed. Results of EVAR are favorable, even in the older higher-risk population of patients who are poor candidates for surgery. Women who undergo endovascular aneurysm repair are at higher risk of aneurysm rupture and surgical conversion than men but exhibit the same low risk of aneurysm related death as men. Thus, EVAR is a safe, effective, and durable treatment for anatomically suited patients with infrarenal AAA. 
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